perimenostage

Last checked September 2026 against 25 sources · Editorial policy

HRT benefits and risks

The main benefits of HRT are relief of hot flashes, night sweats, sleep problems, low mood and vaginal dryness, and protection against osteoporosis and fractures. The main risks are a small rise in breast cancer with combined HRT and, with tablets, in blood clots and stroke. For women under 60 or within 10 years of menopause without specific risks, the benefits usually outweigh the risks.

HRT relieves hot flashes, sleep and mood symptoms and protects bone. Breast cancer, clot and stroke risk depend on type, route and age. The numbers, plainly.

Video: HRT, explained: benefits, risks and the real numbers

Read the transcript (793 words)▾

My friend said HRT causes cancer. My aunt said it saved her life. My doctor said, let's look at the numbers.

Good doctor. Let's do exactly that: what hormone therapy is, what it helps, what the big study really found, the risks in plain numbers, and how to choose. One topic a week, every number sourced. Subscribe, and the next one finds you.

Hormone therapy replaces the estrogen your ovaries are making less of. If you still have a uterus, you also take a progestogen, because estrogen on its own can thicken the uterine lining. Estrogen comes as a patch, a gel, a spray or a tablet. The progestogen can be a tablet, such as micronized progesterone, or a hormonal IUD. Separate from all of this is low-dose vaginal estrogen, a cream, tablet or ring for dryness and bladder symptoms, which works mostly where it's applied.

For hot flashes and night sweats, it's the most effective option: estrogen cuts how often they happen by about seventy-five percent. Guidelines also list sleep problems, and low mood and anxiety that start with menopause, among the symptoms it can relieve. For vaginal dryness, low-dose vaginal estrogen improves symptom severity by sixty to eighty percent. And it protects bone. In SWAN, women lost more than seven percent of their spine bone density in just the three years around the final period. While you take hormone therapy, your risk of fractures is lower.

So why are so many women afraid of it? In 2002, the Women's Health Initiative trial stopped early, headlines linked hormone therapy with breast cancer and heart attacks, and use dropped sharply around the world. But that trial gave an older type of estrogen tablet, with a synthetic progestin, to women whose average age was sixty-three, older than most women who start it for symptoms. Eighteen years of follow-up later, the picture is calmer. Deaths from any cause: 27.1 percent with hormones, 27.6 percent with placebo. No difference in deaths from heart disease or cancer. And women who started in their fifties did better than women who started in their seventies.

Here are the risks that remain, in real numbers. Breast cancer. With combined hormone therapy, the UK health service estimates around five extra cases for every thousand women who take it for five years. With estrogen alone, for women without a uterus, there's little or no increase. Blood clots. Estrogen tablets raise the risk, by about one and a half times in a study of more than eighty thousand women with clots. Patches, gels and sprays didn't raise it at all. Put together, in the big US trial, combined hormones in women aged fifty to fifty-nine meant twelve extra serious health events per ten thousand women a year, about one in eight hundred. With estrogen alone in that age group, there were nineteen fewer. For healthy women under sixty, or within ten years of their last period, the Menopause Society finds the benefits generally outweigh the risks.

How it's given matters. If you have risks for clots, such as a past clot or a higher weight, patches, gels and sprays are usually preferred. Start with the lowest dose that controls your symptoms. If you have a uterus, the progestogen matters too: micronized progesterone or a hormonal IUD are common choices. You'll also hear about bioidentical hormones. Regulated bioidentical estradiol and progesterone already exist on prescription. Custom-compounded creams and pellets are different: they aren't FDA-approved, and their doses aren't standardized. In a US survey, eighty-six percent of women didn't know that.

Hot flashes often start to ease within days to weeks, and it can take up to three months to feel the full effect. Breast tenderness, headaches and spotting are common at first and usually settle within about three months. Irregular spotting can last three to six months on a new regimen. If side effects don't settle, the dose, the type or the route can be changed. Give each change three months, and keep a short symptom diary for your review.

Talk it through carefully with your doctor if you've had breast cancer, a blood clot, a stroke or liver disease. And on hormone therapy, a few things need checking promptly: pain or swelling in one leg, a new breast lump, or bleeding that continues after six months. Chest pain or sudden breathlessness: call 911.

Hormone therapy isn't right for everyone, and it isn't the danger the old headlines made it. It's a decision you can make with real numbers. Find your stage in two minutes at perimenostage.com, and bring your questions to your doctor.

My friend, my aunt, my doctor. The numbers were the tiebreaker.

Next week: lifting weights in perimenopause, and what one trial found for hot flashes. Subscribe so it finds you.

Every number in this video is sourced in the YouTube description.

HRT benefits and risks: expectation vs reality

What people often expect

“HRT shortens your life and causes heart attacks and cancer”

What the evidence shows

In 18 years of follow-up of the WHI trials, HRT didn't change overall, heart or cancer death rates: all-cause mortality was 27.1% with hormones vs 27.6% with placebo. Women who started in their 50s did better than those who started in their 70s. The risks that remain are real but small and depend on the type, route, dose and your age when you start.

HRT benefits and risks, one by one

Benefit: relief of hot flashes and night sweats

HRT's biggest benefit is symptom relief. Systemic estrogen, alone or with a progestogen, reduces hot flash frequency by about 75%, more than any non-hormonal medicine, and both tablets and patches work equally well. Relief often starts within days to weeks, with the full effect by about 3 months. Because hot flashes last a median of 7.4 years, this benefit can matter for a long time.

Learn more →

Benefit: sleep, mood and vaginal symptoms

The NHS lists sleep problems, anxiety and low mood caused by menopause, and vaginal dryness among the symptoms HRT treats. HRT is also the most effective treatment for genitourinary syndrome of menopause, and low-dose vaginal estrogen improves vaginal symptoms by about 60% to 80% on its own. The NHS adds that HRT can help maintain muscle strength, alongside exercise.

Learn more →

Benefit: bone protection

Estrogen prevents bone loss and fractures. In the WHI trials, hip fractures were reduced with both combined and estrogen-only HRT. This matters most if menopause comes before 45, when the NHS says HRT is particularly important to prevent osteoporosis. For bone protection alone in older women, FDA labels advise considering non-estrogen medicines first. In the WHI trials, the benefit on fractures faded after women stopped taking HRT.

Learn more →

Risk: breast cancer

Combined HRT slightly raises breast cancer risk: the NHS puts it at around 5 extra cases per 1,000 women over 5 years, and the risk falls after stopping. Estrogen alone has little or no effect; in the WHI trial, women on estrogen alone had fewer breast cancers than on placebo. A worldwide analysis estimated 5 years of combined HRT from age 50 causes one extra cancer by age 69 per 50 users on daily progestogen and per 200 on estrogen alone.

Learn more →

Risk: blood clots, stroke and gallbladder disease

Estrogen tablets raise the risk of blood clots: in UK data, the odds ratio was 1.58 for tablets but 0.93 for patches and gels, which showed no increased risk. Tablets also slightly raise stroke risk, while low-dose patches weren't linked with stroke. Gallbladder disease rose with tablets (relative risk 1.74) much more than with patches (1.17). Among tablets, estradiol carried a lower clot risk than conjugated estrogens.

Learn more →

Risk: uterine cancer with estrogen alone

In women with a uterus, estrogen without a progestogen raises the risk of endometrial cancer. That's why combined HRT is used unless you've had a hysterectomy, and why the FDA kept this boxed warning when it removed others in 2025. With the right progestogen dose, this risk is controlled. Bleeding that starts after several months of HRT should be checked.

Learn more →

Heart disease, dementia and diabetes

The NHS says HRT has little or no effect on the risk of coronary heart disease, it isn't known whether it reduces dementia risk, and it doesn't increase the risk of type 2 diabetes. In the WHI trial, diabetes was reduced. Dementia risk rose in women who started HRT at 65 or older. HRT isn't recommended to prevent heart disease or other chronic conditions, according to the US Preventive Services Task Force.

Why age and timing change the balance

In the WHI trials, combined HRT caused 12 excess serious events per 10,000 women a year aged 50 to 59 but 38 at 70 to 79; estrogen alone caused 19 fewer events at 50 to 59 and 51 more at 70 to 79. Starting after 60 or more than 10 years after menopause carries higher absolute risks of heart disease, stroke, clots and dementia. Updated FDA labels now advise considering starting before 60 or within 10 years.

Benefits and risks of HRT after 60, 65 and 70

You can continue HRT beyond 60 if the benefits still outweigh the risks for you; there's no fixed limit, and your doctor will review it each year. Starting for the first time after 60 is less favorable. Low-dose vaginal estrogen is the exception: the NHS says it doesn't increase the risk of breast cancer or clots and can be used long term at any age.

HRT benefits and risks by the numbers

From the studies on this page

  • reduction in hot flash frequency with systemic estrogen

    75%

  • all-cause mortality with HRT vs placebo over 18 years in the WHI trials

    27.1% vs 27.6%

5 per 1,000

extra breast cancer cases in women taking combined HRT for 5 years

12 per 10,000

excess serious events a year with combined HRT in women aged 50 to 59 in the WHI trial

WHI used oral conjugated estrogens and medroxyprogesterone in women with an average age of 63. Risks with transdermal estradiol and micronized progesterone started near menopause are likely to be lower for clots and stroke.

How to get the benefits of HRT with the lowest risk

  • Start before 60 or within 10 years of menopause

    Strong evidence

    The benefit-risk balance is most favorable in this window. The North American Menopause Society and updated FDA labels both point to it, and WHI data show far fewer excess events in women who started in their 50s than in their 70s. If you're older and considering HRT for the first time, the decision needs a closer look at your individual risks.

  • Choose transdermal estrogen if you have clot risks

    Strong evidence

    Patches, gels and sprays don't raise the risk of blood clots and carry less gallbladder risk than tablets. They're the usual choice if you're overweight, have had a clot, or have other clot risk factors. Low-dose patches also weren't linked with stroke in a large UK study, unlike tablets.

    Related guide →
  • Use the lowest dose that controls symptoms

    First step

    Lower doses cause fewer side effects, and high-dose patches were linked with stroke while low-dose patches weren't. Start low and increase only if symptoms persist after 3 months. Menopause guidance notes that higher starting doses are more likely to cause side effects, and that blood tests are rarely needed to set the dose.

    Related guide →
  • Protect the uterus with the right progestogen

    Strong evidence

    If you have a uterus, use a progestogen at an adequate dose, such as micronized progesterone or a 52 mg hormonal IUD. Micronized progesterone may carry less risk for clots and breast cancer than some synthetic progestogens, although the evidence isn't strong. The IUD can stay in for 5 years as part of HRT.

  • Keep up with screening

    First step

    Attend mammograms while on HRT, report breast changes, and get any bleeding after the first 6 months checked. US guidelines recommend a mammogram every 2 years from 40 to 74. Going to your yearly HRT review is the moment to recheck whether the balance of benefits and risks still favors continuing.

When to review the benefits and risks of HRT with a doctor

  • Deciding whether to start HRT

    Talk it through with a doctor, especially if you have a personal or family history of breast cancer, clots, stroke or liver disease.

    More →
  • Your yearly HRT review

    Review the benefits and risks each year, and whether to adjust or continue.

  • A breast lump or change, or bleeding after 6 months on HRT

    See a doctor promptly.

  • Urgent: Pain or swelling in one leg, or chest pain with breathlessness

    Leg symptoms: call a doctor now. Chest pain or breathlessness: call 911.

HRT pros and cons: questions women ask

What are the benefits of HRT?

Relief of hot flashes, night sweats, sleep problems, anxiety, low mood and vaginal dryness, plus protection against osteoporosis and fractures. The NHS says it can help muscle strength too. Most women notice symptom relief within weeks.

What are the pros and cons of HRT?

Pros: the most effective hot flash treatment, better sleep and mood, relief of vaginal symptoms and bone protection. Cons: a small rise in breast cancer with combined HRT, a higher clot and stroke risk with tablets, side effects in the first months, and, for estrogen alone with a uterus, uterine cancer risk.

Does HRT work?

Yes. Systemic estrogen reduces hot flash frequency by about 75%, and it's the most effective treatment for hot flashes and genitourinary symptoms. It can take up to 3 months to work fully. If it hasn't helped after 3 months, a dose or type change usually does.

What are the benefits of HRT after 50?

Women in their 50s get the most favorable balance: symptom relief and bone protection with the lowest absolute risks. In the WHI trial, estrogen alone in women aged 50 to 59 caused 19 fewer serious events per 10,000 a year than placebo.

What are the benefits of HRT after 60 or 65?

If you're already on HRT and it's working, you can continue with yearly reviews. Starting for the first time after 60 carries higher absolute risks of heart disease, stroke, clots and dementia, so the benefits need to be clearer. Vaginal estrogen can be used at any age.

What are the benefits of HRT after 70?

Few women start systemic HRT at 70, because absolute risks are higher: in the WHI trials, excess events were highest in women aged 70 to 79. Low-dose vaginal estrogen remains useful for vaginal and urinary symptoms at this age.

Does HRT increase cancer risk?

Combined HRT slightly raises breast cancer risk, around 5 extra cases per 1,000 women over 5 years. Estrogen alone raises uterine cancer risk if you have a uterus and don't take a progestogen. In the WHI trials, overall cancer deaths over 18 years were no different from placebo.

What are the benefits of HRT in perimenopause?

The same symptom relief, often when symptoms are at their worst, plus regulated bleeding on sequential HRT. You don't need to wait for your periods to stop. It isn't a contraceptive, so you'll still need contraception.

Related →

Which HRT is best for skin and hair?

No HRT type has been proven best for skin or hair. Estrogen helps maintain skin collagen and thickness, and falling estrogen is linked with hair thinning, but trial evidence that HRT improves hair is limited.

Related →

Sources

  1. NHS. Benefits and risks of hormone replacement therapy (HRT).
  2. The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
  3. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-68.
  4. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017;318(10):927-938.
  5. Crandall CJ, Mehta JM, Manson JE. Management of Menopausal Symptoms: A Review. JAMA. 2023;329(5):405-420.
  6. NHS. Oestrogen tablets, patches, gel and spray: common questions.
  7. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-9.
  8. Prescribing information: Estradiol tablets USP. Teva Pharmaceuticals, 2024. DailyMed, US National Library of Medicine.
  9. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159-1168.
  10. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810.
  11. Renoux C, Dell'aniello S, Garbe E, et al. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010;340:c2519.
  12. Liu B, Beral V, Balkwill A, et al. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ. 2008;337:a386.
  13. Prescribing information: Divigel (estradiol gel 0.1%). Vertical Pharmaceuticals, 2026. DailyMed, US National Library of Medicine.
  14. US Food and Drug Administration. HHS advances women's health, removes misleading FDA warnings on hormone replacement therapy. November 10, 2025.
  15. NHS. Oestrogen tablets, patches, gel and spray: side effects.
  16. US Preventive Services Task Force. Hormone therapy in postmenopausal persons: primary prevention of chronic conditions. 2022.
  17. NHS. When to take hormone replacement therapy (HRT).
  18. Women's Health Concern / British Menopause Society. Fact sheet: HRT types, doses and regimens.
  19. British Menopause Society. Tool for clinicians: HRT preparations and equivalent alternatives. 2024.
  20. US Preventive Services Task Force. Breast cancer: screening. 2024.
  21. NHS. About hormone replacement therapy (HRT).
  22. National 911 Program. 911.gov.
  23. NHS. Types of hormone replacement therapy (HRT).
  24. Thornton MJ. Estrogens and aging skin. Dermatoendocrinol. 2013;5(2):264-70.
  25. Gupta AK, Economopoulos V, Mann A, et al. Menopause and hair loss in women: Exploring the hormonal transition. Maturitas. 2025;198:108378.

See our editorial policy.

Related guides

Doctor-ready summary

Your stage in 2 minutes.

You leave with a stage estimate and a one-page summary sized for a short appointment.

Begin 2-minute stage check

Private · No app download

Sample report

Stage estimateLate transition
Sleep driving burden · TSH worth ruling out